Molecular biology of bladder cancer

被引：27

作者：

Luis, Nuno M. ^{[1
]}

Lopez-Knowles, Elena ^{[1
]}

Real, Francisco X. ^{[1
,2
]}

机构：

[1] Inst Municipal Invest Med, Unitat Biol Cellular & Mol, E-08003 Barcelona, Spain

[2] Univ Pompeu Fabra, Barcelona, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2007年 / 9卷 / 01期

关键词：

bladder; FGFR3; genetic alterations; p53; rb; urothelial carcinoma;

D O I：

10.1007/s12094-007-0003-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bladder cancer is a major cause of health expenses and it presents formidable clinical challenges. Two types of tumors have been identified, papillary and non-papillary. The former are mainly characterized by FGFR3 and chromosome 9 alterations and a low frequency of Tp53 alterations. The latter are characterized by a high frequency of alterations in genes in the p53 and Rb pathways. Chromosome 9 alterations, specially in 9q, are crucial to bladder cancer development and occur in both types of tumors. Progression of some superficial tumors ( mainly TaG3 and T1G3) to high-grade, invasive, carcinomas provides evidence of some overlap between the two pathways. Distinct gene expression profiles have been identified in superficial and invasive tumors. The stage is now ready for the clinical application of this knowledge.

引用

页码：5 / 12

页数：8

共 73 条

[21]

del Muro XG, 2000, EUR J CANCER, V36, P357

[22] Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma [J].

Dhawan, D. ;

Hamdy, F. C. ;

Rehman, I. ;

Patterson, J. ;

Cross, S. S. ;

Feeley, K. M. ;

Stephenson, Y. ;

Meuth, M. ;

Catto, J. W. F. .

JOURNAL OF PATHOLOGY, 2006, 209 (03) :336-343

[23] Identifying distinct classes of bladder carcinoma using microarrays [J].

Dyrskjot, L ;

Thykjaer, T ;

Kruhoffer, M ;

Jensen, JL ;

Marcussen, N ;

Hamilton-Dutoit, S ;

Wolf, H ;

Orntoft, TF .

NATURE GENETICS, 2003, 33 (01) :90-96

[24] Defining a 0.5-Mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction [J].

Evans, AJ ;

Gallie, BL ;

Jewett, MAS ;

Pond, GR ;

Vandezande, K ;

Underwood, J ;

Fradet, Y ;

Lim, G ;

Marrano, P ;

Zielenska, M ;

Squire, JA .

AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (01) :285-293

[25] Amplification and overexpression of E2F3 in human bladder cancer [J].

Feber, A ;

Clark, J ;

Goodwin, G ;

Dodson, AR ;

Smith, PH ;

Fletcher, A ;

Edwards, S ;

Flohr, P ;

Falconer, A ;

Roe, T ;

Kovacs, G ;

Dennis, N ;

Fisher, C ;

Wooster, R ;

Huddart, R ;

Foster, CS ;

Cooper, CS .

ONCOGENE, 2004, 23 (08) :1627-1630

[26]

FERLAY JBF, 2000, CANC INCIDENCE MORTA

[27]

FREREBELDA MA, 2004, HUM PATHOL, V35, P817

[28] Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies [J].

Hafner, C ;

Knuechel, R ;

Stoehr, R ;

Hartmann, A .

INTERNATIONAL JOURNAL OF CANCER, 2002, 101 (01) :1-6

[29]

Hartmann A, 2002, CANCER RES, V62, P809

[30] Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas [J].

Hernandez, Silvia ;

Lopez-Knowles, Elena ;

Lloreta, Josep ;

Kogevinas, Manolis ;

Amoros, Alex ;

Tardon, Adonina ;

Carrato, Alfredo ;

Serra, Consol ;

Malats, Nuria ;

Real, Francisco X. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (22) :3664-3671

← 1 2 3 4 5 6 7 8 →